Publicaciones en las que colabora con Ana Lluch Hernández (35)

2022

  1. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A

    Nature Communications, Vol. 13, Núm. 1

2020

  1. HDAC5 inhibitors as a potential treatment in breast cancer affecting very young women

    Cancers, Vol. 12, Núm. 2

  2. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

  3. miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker

    Breast Cancer: Basic and Clinical Research, Vol. 14

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. Acceleration in the DNA methylation age in breast cancer tumours from very young women

    Scientific Reports, Vol. 9, Núm. 1

  3. Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator

    Breast Cancer: Basic and Clinical Research, Vol. 13

2018

  1. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER + breast cancer

    Nature Cell Biology, Vol. 20, Núm. 2, pp. 211-221

  2. Erratum to: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer (Nature Cell Biology, (2018), 20, 2, (211-221), 10.1038/s41556-017-0021-z)

    Nature Cell Biology

  3. Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. Critically short telomeres and toxicity of chemotherapy in early breast cancer

    Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482

  4. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer

    Cancer Research, Vol. 77, Núm. 9, pp. 2213-2221

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2015

  1. In response: Genomic profile of breast cancer

    Expert Review of Pharmacoeconomics and Outcomes Research

  2. Patterns of HER2 gene amplification and response to anti-HER2 therapies

    PLoS ONE, Vol. 10, Núm. 6

2014

  1. Genomic profile of breast cancer: Cost-effectiveness analysis from the Spanish National Healthcare System perspective

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, Núm. 6, pp. 889-899

  2. Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk

    European Journal of Cancer, Vol. 50, Núm. 18, pp. 3168-3177

  3. MicroRNA profile in very young women with breast cancer

    BMC Cancer, Vol. 14, Núm. 1